CN110893175A - 一种双氯芬酸钠肠溶片 - Google Patents

一种双氯芬酸钠肠溶片 Download PDF

Info

Publication number
CN110893175A
CN110893175A CN201911227676.3A CN201911227676A CN110893175A CN 110893175 A CN110893175 A CN 110893175A CN 201911227676 A CN201911227676 A CN 201911227676A CN 110893175 A CN110893175 A CN 110893175A
Authority
CN
China
Prior art keywords
diclofenac sodium
percent
coated tablet
enteric
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201911227676.3A
Other languages
English (en)
Inventor
林凡友
聂昌盛
薛颖
毛传伟
高聪杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tong Ren Pharmaceutical Co Ltd
Original Assignee
Tong Ren Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tong Ren Pharmaceutical Co Ltd filed Critical Tong Ren Pharmaceutical Co Ltd
Priority to CN201911227676.3A priority Critical patent/CN110893175A/zh
Publication of CN110893175A publication Critical patent/CN110893175A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明属于医药技术领域,尤其涉及一种双氯芬酸钠肠溶片。该双氯芬酸钠肠溶片重量百分比的组分为:双氯芬酸钠18%‑52%,丙烯酸树脂L100‑55 46%‑80%,润滑剂0.3%‑2%,上述各组份之和达到100%。本发明所得的双氯芬酸钠片剂辅料用量少、稳定性好、工艺简单,且药性副作用小,安全性好。

Description

一种双氯芬酸钠肠溶片
技术领域
本发明属于医药技术领域,尤其涉及一种双氯芬酸钠肠溶片。
背景技术
双氯芬酸钠是一种常见的消炎镇痛药。常用于缓解类风湿关节炎、骨关节炎。脊柱关节病、痛风性关节炎、风湿性关节炎等各种慢性关节炎的急性发作期或持续性的关节肿痛症状;各种软组织风湿性疼痛,如肩痛、腱鞘炎、滑囊炎肌痛及运动后损伤性疼痛等;急性的轻、中度疼痛如:手术、创伤、劳损后等的疼痛;原发性痛经,牙痛,头痛等。
无论大剂量还是小剂量双氯芬酸钠片剂,长时间使用时其主要副作用是对肠胃道的刺激,解决这一问题最普遍的方法就是制备其肠溶片剂,但普通的肠溶片剂即使到达肠内也因为迅速崩解溶出而产生肠道副作用,且片剂受胃幽门括约肌影响很大,研究表明其从胃部到小肠的时间为15分钟到7小时不等,从而容易造成血药浓度不稳定,小肠局部浓度过高,加剧肠道刺激。
发明内容
针对以上技术问题,本发明提供了一种辅料用量少、稳定性好、工艺简单的双氯芬酸钠肠溶片。
为了解决以上技术问题,本发明采用如下技术方案:一种双氯芬酸钠肠溶片,其重量百分比的组分为:
双氯芬酸钠 18%-52%
丙烯酸树脂L100-55 46%-80%
润滑剂 0 .3%-2%,
上述各组份之和达到100%。
优选的:上述双氯芬酸钠肠溶片,其重量百分比的组分为:
双氯芬酸钠 29%-38%
丙烯酸树脂L100-55 60%-70%
润滑剂 0 .3%-2%,
上述各组份之和达到100%。
进一步:在上述每片含有双氯芬酸钠25-100mg。所述的润滑剂为硬脂酸镁、微粉硅胶和滑石粉中的一种或多种。
所述的润滑剂为硬脂酸镁、微粉硅胶和滑石粉中的一种或多种。
所述的润滑剂为硬脂酸镁。
本发明涉及的双氯芬酸钠肠溶片及其制备方法具有以下优点:
(1)辅料种类少,片剂稳定性高。本发明仅采用了肠溶材料和润滑剂,未添加其他任何辅料,提高了双氯芬酸钠的稳定性;
(2)耐酸力良好,pH=6.8的磷酸盐缓冲液中快速溶出。体外释放度实验表明:
本发明片剂在0 .1mol/L盐酸中2小时释放不到1 .5%,且片剂完整,外观无变化;
在pH=6.8磷酸盐缓冲液中,片剂很快溶蚀,药物迅速溶出。
(3)不用包肠溶衣,制备工艺简单,适合工业化生产。
另外,双氯芬酸钠片剂,长时间使用时其主要副作用是对肠胃道的刺激,肠溶片可以减少药物对胃的局部刺激,也减少了胃液对药物的破坏。双氯芬酸钠肠溶片在胃里不崩解,在肠道中吸收,对胃刺激小。本发明采用乙醇溶解双氯芬酸钠、丙烯酸树脂L100-55,干燥、过筛,可以使物料充分混合均匀,同时采用丙烯酸树脂L100-55,很好的避免了结块问题。乙醇作为最常用的有机试剂,在片剂领域应用非常广泛,安全防护措施非常全面,并不会存在很严重的安全隐患。同时乙醇的易挥发性决定了它在干燥之后几乎没有溶剂残留。
所以本发明所得的双氯芬酸钠片剂辅料用量少、稳定性好、工艺简单,且药性副作用小,安全性好。
具体实施方式
下面通过实例进一步说明本发明。本发明实例的配方和制备方法是用于说明本发明,而不是对本发明的限制,在本发明的构思前提下有关双氯芬酸钠肠溶片的配方及制备方法的简单改进都属于本发明要求保护的范围。
实施例1
双氯芬酸钠100g、丙烯酸树脂L100-55 100g搅拌溶解在500mL乙醇中,于真空烘箱中40℃干燥24小时,粉碎,过30目筛,得到双氯芬酸钠肠溶片分散体;将肠溶片分散片与硬
脂酸镁混合均匀,用旋转压片机压缩成型。
实施例2
双氯芬酸钠25g、丙烯酸树脂L100-55 100g搅拌溶解在1000mL乙醇中,于真空烘箱中45℃干燥24小时,粉碎,过24目筛,得到双氯芬酸钠肠溶片分散体;将得到的肠溶片分散体与硬脂酸镁1.2g、微粉硅胶1 .0g混合均匀,用旋转压片机压缩成型。
本发明所得的双氯芬酸钠肠溶片辅料用量少、稳定性好、工艺简单,且药性副作用小,安全性好。

Claims (4)

1.一种双氯芬酸钠肠溶片,其重量百分比的组分为:
双氯芬酸钠 18%-52%
丙烯酸树脂L100-55 46%-80%
润滑剂 0 .3%-2%,
上述各组份之和达到100%。
2.根据权利要求1所述的双氯芬酸钠肠溶片,其重量百分比的组分为:
双氯芬酸钠 29%-38%
丙烯酸树脂L100-55 60%-70%
润滑剂 0 .3%-2%,
上述各组份之和达到100%。
3.根据权利要求1或2所述的双氯芬酸钠肠溶片,其特征在于:每片含有双氯芬酸钠25-100mg。
4.根据权利要求1或者2所述的双氯芬酸钠肠溶片,其特征在于:所述的润滑剂为硬脂酸镁、微粉硅胶和滑石粉中的一种或多种。
CN201911227676.3A 2019-12-04 2019-12-04 一种双氯芬酸钠肠溶片 Pending CN110893175A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911227676.3A CN110893175A (zh) 2019-12-04 2019-12-04 一种双氯芬酸钠肠溶片

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911227676.3A CN110893175A (zh) 2019-12-04 2019-12-04 一种双氯芬酸钠肠溶片

Publications (1)

Publication Number Publication Date
CN110893175A true CN110893175A (zh) 2020-03-20

Family

ID=69788535

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201911227676.3A Pending CN110893175A (zh) 2019-12-04 2019-12-04 一种双氯芬酸钠肠溶片

Country Status (1)

Country Link
CN (1) CN110893175A (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0383967A1 (en) * 1989-02-17 1990-08-29 Dojin Iyaku-Kako Co., Ltd. Long acting diclofenac sodium preparation
CN102846572A (zh) * 2012-10-10 2013-01-02 德州德药制药有限公司 双氯芬酸钠缓释片及其制备方法
CN106109426A (zh) * 2016-06-23 2016-11-16 广东肇庆星湖生物科技股份有限公司 一种双氯芬酸钠肠溶片及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0383967A1 (en) * 1989-02-17 1990-08-29 Dojin Iyaku-Kako Co., Ltd. Long acting diclofenac sodium preparation
CN102846572A (zh) * 2012-10-10 2013-01-02 德州德药制药有限公司 双氯芬酸钠缓释片及其制备方法
CN106109426A (zh) * 2016-06-23 2016-11-16 广东肇庆星湖生物科技股份有限公司 一种双氯芬酸钠肠溶片及其制备方法

Similar Documents

Publication Publication Date Title
Jindal et al. Synthesis of thiolated alginate and evaluation of mucoadhesiveness, cytotoxicity and release retardant properties
CN100436525C (zh) 一种海藻酸钠/壳聚糖共混凝胶粒的制备方法
EP2441779A1 (en) Process for the preparation of sevelamer hydrochloride and formulation thereof
US20200054565A1 (en) Monolithic tablets based on carboxyl polymeric complexes for controlled drug release
CN105434465B (zh) 一种防治关节炎的药物组合物及其制备方法
US20200108017A1 (en) Two speed monolithic system for controlled release of drugs
CN110507620B (zh) 一种复方硫酸氨基葡萄糖分散片及其制备方法
CN106109426A (zh) 一种双氯芬酸钠肠溶片及其制备方法
CN102952280A (zh) 一种可用于制备植物胶囊的羟丙甲纤维素共聚物及其制备方法
CN110893174A (zh) 双氯芬酸钠肠溶片的制备方法
CN103610658B (zh) 一种免疫调节剂缓释剂及其制备方法
CN101297790A (zh) 扎托布洛芬缓释制剂及其制备方法
CN110893175A (zh) 一种双氯芬酸钠肠溶片
CN103263395A (zh) 一种替米沙坦片剂及其制备方法
WO2017013682A1 (en) Process of preparation of co-processed polymer and it's pharmaceutical application
CN110960499A (zh) 一种泊沙康唑胃漂浮片及其制备方法
JP4864369B2 (ja) チアミン類の安定化方法
CN102871994A (zh) 氟比洛芬对乙酰氨基酚酯环糊精包合物及其制备方法
CN103127019B (zh) 一种氟苯尼考分散片及其制备方法和用途
EP2793853B1 (en) Pharmaceutical formulations of flurbiprofen and glucosamin
CN107375938B (zh) 一种盐酸氨基葡萄糖的粘合剂、片剂及其制备方法
CN103142533A (zh) 一种依托泊苷肠溶片
CN103142545B (zh) 一种依托泊苷肠溶胶囊
CN1939292B (zh) 口服药物制剂及口服缓释制剂
CN115192535B (zh) 一种氨糖美辛肠溶片及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20200320